Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Alkaline Ceramidase 1 Protects Mice from Premature Hair Loss by Maintaining the Homeostasis of Hair Follicle Stem Cells.

Lin CL, Xu R, Yi JK, Li F, Chen J, Jones EC, Slutsky JB, Huang L, Rigas B, Cao J, Zhong X, Snider AJ, Obeid LM, Hannun YA, Mao C.

Stem Cell Reports. 2017 Nov 14;9(5):1488-1500. doi: 10.1016/j.stemcr.2017.09.015. Epub 2017 Oct 19.

2.

Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.

Mattheolabakis G, Wang R, Rigas B, Mackenzie GG.

Int J Oncol. 2017 Oct;51(4):1035-1044. doi: 10.3892/ijo.2017.4103. Epub 2017 Aug 25.

3.

Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.

Mattheolabakis G, Papayannis I, Yang J, Vaeth BM, Wang R, Bandovic J, Ouyang N, Rigas B, Mackenzie GG.

Cancer Prev Res (Phila). 2016 Jul;9(7):624-34. doi: 10.1158/1940-6207.CAPR-15-0344. Epub 2016 May 2.

4.

The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.

Bartels LE, Mattheolabakis G, Vaeth BM, LaComb JF, Wang R, Zhi J, Komninou D, Rigas B, Mackenzie GG.

Carcinogenesis. 2016 Apr;37(4):420-429. doi: 10.1093/carcin/bgw017. Epub 2016 Feb 10.

5.

NSAIDs and Colorectal Cancer Control: Promise and Challenges.

Tsioulias GJ, Go MF, Rigas B.

Curr Pharmacol Rep. 2015 Oct 1;1(5):295-301. Epub 2015 May 14.

6.

Altered Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis in APCMin/+ Mice.

Son JS, Khair S, Pettet DW 3rd, Ouyang N, Tian X, Zhang Y, Zhu W, Mackenzie GG, Robertson CE, Ir D, Frank DN, Rigas B, Li E.

PLoS One. 2015 Jun 29;10(6):e0127985. doi: 10.1371/journal.pone.0127985. eCollection 2015.

7.
8.

Repurposing the antipsychotic trifluoperazine as an antimetastasis agent.

Pulkoski-Gross A, Li J, Zheng C, Li Y, Ouyang N, Rigas B, Zucker S, Cao J.

Mol Pharmacol. 2015;87(3):501-12. doi: 10.1124/mol.114.096941. Epub 2014 Dec 31.

9.

Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.

Wong CC, Cheng KW, Papayannis I, Mattheolabakis G, Huang L, Xie G, Ouyang N, Rigas B.

Pharm Res. 2015 May;32(5):1663-75. doi: 10.1007/s11095-014-1565-2. Epub 2014 Nov 13.

10.

Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.

Huang L, Wong CC, Cheng KW, Rigas B.

PLoS One. 2014 Nov 4;9(11):e111720. doi: 10.1371/journal.pone.0111720. eCollection 2014.

11.

A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.

Cheng KW, Nie T, Ouyang N, Alston N, Wong CC, Mattheolabakis G, Papayannis I, Huang L, Rigas B.

Int J Pharm. 2014 Dec 30;477(1-2):236-43. doi: 10.1016/j.ijpharm.2014.10.019. Epub 2014 Oct 11.

PMID:
25311177
12.

Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen.

Mattheolabakis G, Wong CC, Sun Y, Amella CA, Richards R, Constantinides PP, Rigas B.

J Pharmacol Exp Ther. 2014 Oct;351(1):61-6. doi: 10.1124/jpet.114.217208. Epub 2014 Jul 21.

13.

The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.

Xie G, Cheng KW, Huang L, Rigas B.

Biochem Pharmacol. 2014 Sep 15;91(2):249-55. doi: 10.1016/j.bcp.2014.07.007. Epub 2014 Jul 18.

14.

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B.

BMC Cancer. 2014 Feb 28;14:141. doi: 10.1186/1471-2407-14-141.

15.

Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate.

Murray OT, Wong CC, Vrankova K, Rigas B.

Int J Oncol. 2014 Feb;44(2):521-9. doi: 10.3892/ijo.2013.2190. Epub 2013 Nov 27.

16.

A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.

Mackenzie GG, Bartels LE, Xie G, Papayannis I, Alston N, Vrankova K, Ouyang N, Rigas B.

Neoplasia. 2013 Oct;15(10):1184-95.

17.

Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.

Cheng KW, Wong CC, Mattheolabakis G, Xie G, Huang L, Rigas B.

Int J Oncol. 2013 Sep;43(3):895-902. doi: 10.3892/ijo.2013.1995. Epub 2013 Jun 27.

18.

Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.

Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B.

PLoS One. 2013 May 1;8(5):e61532. doi: 10.1371/journal.pone.0061532. Print 2013.

19.

Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.

Cheng KW, Wong CC, Alston N, Mackenzie GG, Huang L, Ouyang N, Xie G, Wiedmann T, Rigas B.

Mol Cancer Ther. 2013 Aug;12(8):1417-28. doi: 10.1158/1535-7163.MCT-13-0006-T. Epub 2013 May 3.

20.

Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.

Mattheolabakis G, Mackenzie GG, Huang L, Ouyang N, Cheng KW, Rigas B.

Pharm Res. 2013 Jun;30(6):1471-82. doi: 10.1007/s11095-012-0953-8. Epub 2013 Mar 13.

21.

Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.

Xie G, Zhou D, Cheng KW, Wong CC, Rigas B.

Biochem Pharmacol. 2013 Apr 15;85(8):1195-202. doi: 10.1016/j.bcp.2013.01.031. Epub 2013 Feb 8.

22.

The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.

Zhou D, Papayannis I, Mackenzie GG, Alston N, Ouyang N, Huang L, Nie T, Wong CC, Rigas B.

Carcinogenesis. 2013 Apr;34(4):943-51. doi: 10.1093/carcin/bgs394. Epub 2013 Jan 21.

23.

Platinum folate nanoparticles toxicity: cancer vs. normal cells.

Mironava T, Simon M, Rafailovich MH, Rigas B.

Toxicol In Vitro. 2013 Mar;27(2):882-9. doi: 10.1016/j.tiv.2013.01.005. Epub 2013 Jan 11.

PMID:
23318730
24.

Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives.

Mattheolabakis G, Rigas B, Constantinides PP.

Nanomedicine (Lond). 2012 Oct;7(10):1577-90. doi: 10.2217/nnm.12.128. Review.

PMID:
23148540
25.

FT-IR microspectroscopy of mouse colon tissues: insight into the chemistry of carcinogenesis and diagnostic potential.

Cohenford MA, Lim S, Brown C, Chaudhry MA, Sigdel S, Beckelhimer E, Rigas B.

Am J Pathol. 2012 Dec;181(6):1961-8. doi: 10.1016/j.ajpath.2012.08.039. Epub 2012 Oct 10.

PMID:
23063512
26.

MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis.

Ouyang N, Zhu C, Zhou D, Nie T, Go MF, Richards RJ, Rigas B.

PLoS One. 2012;7(7):e41585. doi: 10.1371/journal.pone.0041585. Epub 2012 Jul 23.

27.

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.

Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, Rigas B.

Int J Oncol. 2012 Oct;41(4):1199-203. doi: 10.3892/ijo.2012.1577. Epub 2012 Jul 27.

28.

In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).

Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B.

Pharm Res. 2012 Dec;29(12):3292-301. doi: 10.1007/s11095-012-0821-6. Epub 2012 Jul 11.

29.

Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.

Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B.

Pharm Res. 2012 Nov;29(11):3090-101. doi: 10.1007/s11095-012-0801-x. Epub 2012 Jun 22.

30.

Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.

Zhu C, Cheng KW, Ouyang N, Huang L, Sun Y, Constantinides P, Rigas B.

Stem Cells. 2012 Oct;30(10):2065-75. doi: 10.1002/stem.1139.

31.

Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.

Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B.

Br J Pharmacol. 2012 Sep;167(1):222-32. doi: 10.1111/j.1476-5381.2012.01982.x.

32.

Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.

Wong CC, Cheng KW, Rigas B.

J Pharmacol Exp Ther. 2012 Jun;341(3):572-8. doi: 10.1124/jpet.112.191957. Epub 2012 Mar 23.

33.

Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.

Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, Rigas B.

Breast Cancer Res. 2012 Jan 31;14(1):R20.

34.

Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.

Nie T, Wong CC, Alston N, Aro P, Constantinides PP, Rigas B.

Br J Pharmacol. 2012 Jun;166(3):991-1001. doi: 10.1111/j.1476-5381.2011.01799.x.

35.

Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.

Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, Rigas B.

J Pharmacol Exp Ther. 2012 Feb;340(2):422-32. doi: 10.1124/jpet.111.188508. Epub 2011 Nov 15.

36.

Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.

Mattheolabakis G, Nie T, Constantinides PP, Rigas B.

Pharm Res. 2012 Jun;29(6):1435-43. doi: 10.1007/s11095-011-0619-y. Epub 2011 Nov 10.

37.

Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.

Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, Rigas B.

Cancer Res. 2011 Dec 15;71(24):7617-27. doi: 10.1158/0008-5472.CAN-11-2349. Epub 2011 Oct 24.

38.

The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.

Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B.

Br J Pharmacol. 2012 Apr;165(7):2152-66. doi: 10.1111/j.1476-5381.2011.01705.x.

39.

Structure-activity relationship study of novel anticancer aspirin-based compounds.

Joseph S, Nie T, Huang L, Zhou H, Atmakur K, Gupta RC, Johnson F, Rigas B.

Mol Med Rep. 2011 Sep-Oct;4(5):891-9. doi: 10.3892/mmr.2011.534. Epub 2011 Jul 6.

40.
41.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B.

Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4.

42.

Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.

Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B.

J Pharmacol Exp Ther. 2011 Jun;337(3):876-86. doi: 10.1124/jpet.111.180224. Epub 2011 Mar 21.

43.

Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.

Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B.

Exp Cell Res. 2011 Jun 10;317(10):1359-67. doi: 10.1016/j.yexcr.2011.03.001. Epub 2011 Mar 22. Erratum in: Exp Cell Res. 2012 Jun 10;318(10):1185.

44.

The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats.

Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B.

Br J Pharmacol. 2011 Apr;162(7):1521-33. doi: 10.1111/j.1476-5381.2010.01162.x.

45.

Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.

Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D, Rigas B.

Carcinogenesis. 2010 Nov;31(11):1982-90. doi: 10.1093/carcin/bgq149. Epub 2010 Jul 12.

46.

Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.

Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B.

Gastroenterology. 2010 Oct;139(4):1320-32. doi: 10.1053/j.gastro.2010.06.044. Epub 2010 Jun 20. Erratum in: Gastroenterology. 2012 Mar;142(3):676.

47.

Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.

Zhang Z, Huang L, Zhao W, Rigas B.

Cancer Res. 2010 Mar 15;70(6):2379-88. doi: 10.1158/0008-5472.CAN-09-4204. Epub 2010 Mar 9.

48.
49.

Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.

Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, Gonzalez FJ, Peters JM.

Mol Carcinog. 2009 Oct;48(10):942-52. doi: 10.1002/mc.20546.

50.

Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.

Zhao W, Mackenzie GG, Murray OT, Zhang Z, Rigas B.

Carcinogenesis. 2009 Mar;30(3):512-9. doi: 10.1093/carcin/bgp015. Epub 2009 Jan 9.

Supplemental Content

Support Center